Clinical Trial

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Study acronym: DemonsTTRate
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-13; most recent amendment 2026-04-23.
Trial Details
NCT Number NCT07358078
Lead Sponsor Alnylam Pharmaceuticals
Conditions Transthyretin Amyloidosis With Cardiomyopathy
Enrollment 2,000 participants
Start Date 2026-01-09
Primary Completion 2030-10-23 (estimated)
Study Completion 2030-10-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-24